{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:41:33Z","timestamp":1785372093291,"version":"3.55.0"},"reference-count":115,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>This Clinical Report was retired July 2024.<\/jats:title>\n               <jats:p>Anthrax is a zoonotic disease caused by Bacillus anthracis, which has multiple routes of infection in humans, manifesting in different initial presentations of disease. Because B anthracis has the potential to be used as a biological weapon and can rapidly progress to systemic anthrax with high mortality in those who are exposed and untreated, clinical guidance that can be quickly implemented must be in place before any intentional release of the agent. This document provides clinical guidance for the prophylaxis and treatment of neonates, infants, children, adolescents, and young adults up to the age of 21 (referred to as \u201cchildren\u201d) in the event of a deliberate B anthracis release and offers guidance in areas where the unique characteristics of children dictate a different clinical recommendation from adults.<\/jats:p>","DOI":"10.1542\/peds.2014-0563","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T03:17:05Z","timestamp":1398741425000},"page":"e1411-e1436","source":"Crossref","is-referenced-by-count":48,"title":["Pediatric Anthrax Clinical Management"],"prefix":"10.1542","volume":"133","author":[{"given":"John S.","family":"Bradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Meaney-Delman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AAP COMMITTEE ON INFECTIOUS DISEASES and DISASTER PREPAREDNESS ADVISORY COUNCIL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Fagbuyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Needle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Schonfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Thomas","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Lynn","family":"Byington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Dele","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Aida","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Orenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobeen H.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon E.","family":"Schutze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Rodney E.","family":"Willoughby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theoklis","family":"Zaoutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"issue":"7","key":"2024081912514602600_B1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7205\/MILMED.171.7.589","article-title":"Development of a risk-priority score for category A bioterrorism agents as an aid for public health policy.","volume":"171","author":"MacIntyre","year":"2006","journal-title":"Mil Med"},{"issue":"17","key":"2024081912514602600_B2","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management.","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"2024081912514602600_B3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.mam.2009.07.002","article-title":"Preparedness for an anthrax attack.","volume":"30","author":"Franz","year":"2009","journal-title":"Mol Aspects Med"},{"issue":"9723","key":"2024081912514602600_B4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(10)60573-9","article-title":"Anthrax infection in drug users.","volume":"375","author":"Booth","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2024081912514602600_B5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.1997.03550050074036","article-title":"Biological warfare. A historical perspective.","volume":"278","author":"Christopher","year":"1997","journal-title":"JAMA"},{"issue":"4","key":"2024081912514602600_B6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3201\/eid0504.990418","article-title":"Clinical and epidemiologic principles of anthrax.","volume":"5","author":"Cieslak","year":"1999","journal-title":"Emerg Infect Dis"},{"issue":"22","key":"2024081912514602600_B7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra012892","article-title":"Recognition and management of anthrax\u2014an update.","volume":"345","author":"Swartz","year":"2001","journal-title":"N Engl J Med"},{"issue":"5188","key":"2024081912514602600_B8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.7973702","article-title":"The Sverdlovsk anthrax outbreak of 1979.","volume":"266","author":"Meselson","year":"1994","journal-title":"Science"},{"issue":"10","key":"2024081912514602600_B9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"22","key":"2024081912514602600_B10","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1056\/NEJMicm010777","article-title":"Images in clinical medicine. Cutaneous anthrax infection.","volume":"345","author":"Roche","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2024081912514602600_B11","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130687","article-title":"Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults.","volume":"20","author":"Hendricks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2024081912514602600_B12","unstructured":"Centers for Disease Control and Prevention. Children and anthrax: a fact sheet for clinicians. Available at: www.bt.cdc.gov\/agent\/anthrax\/pediatricfactsheet.asp. Accessed August 21, 2013"},{"issue":"1","key":"2024081912514602600_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006454-200101000-00001","article-title":"Compliance issues related to the selection of antibiotic suspensions for children.","volume":"20","author":"Steele","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"2024081912514602600_B14","volume-title":"Pediatric Preparedness Resource Kit","author":"American Academy of Pediatrics","year":"2013"},{"key":"2024081912514602600_B15","first-page":"228","article-title":"Anthrax","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2012","edition":"29th ed."},{"issue":"3","key":"2024081912514602600_B16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jiph.2010.07.004","article-title":"A review of cutaneous anthrax and its outcome.","volume":"3","author":"Doganay","year":"2010","journal-title":"J Infect Public Health"},{"issue":"6","key":"2024081912514602600_B17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1525-1470.2010.01214.x","article-title":"Clinical findings in children with cutaneous anthrax in eastern Turkey.","volume":"27","author":"Akbayram","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"2024081912514602600_B18"},{"issue":"6","key":"2024081912514602600_B19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1378\/chest.53.6.773","article-title":"Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax).","volume":"53","author":"Doust","year":"1968","journal-title":"Dis Chest"},{"key":"2024081912514602600_B20","first-page":"227","article-title":"Bacillus anthracis dissemination through hosts","volume-title":"Bacillus Anthracis and Anthrax","author":"Glomski","year":"2011"},{"key":"2024081912514602600_B21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/path.1700730219","article-title":"The pathogenesis of anthrax following the administration of spores by the respiratory route.","volume":"73","author":"Ross","year":"1957","journal-title":"J Pathol Bacteriol"},{"issue":"3","key":"2024081912514602600_B22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1086\/346035","article-title":"Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses.","volume":"36","author":"Kuehnert","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2024081912514602600_B23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMcpc1003887","article-title":"Case records of the Massachusetts General Hospital. Case 25\u20132010. A 24-year-old woman with abdominal pain and shock.","volume":"363","author":"Klempner","year":"2010","journal-title":"N Engl J Med"},{"key":"2024081912514602600_B24","first-page":"457","article-title":"Human inhalation anthrax. A report of three fatal cases.","volume":"36","author":"Albrink","year":"1960","journal-title":"Am J Pathol"},{"issue":"4","key":"2024081912514602600_B25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: a century of inhalational anthrax cases from 1900 to 2005.","volume":"144","author":"Holty","year":"2006","journal-title":"Ann Intern Med"},{"issue":"5","key":"2024081912514602600_B26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archinte.158.5.429","article-title":"Anthrax as a potential biological warfare agent.","volume":"158","author":"Pile","year":"1998","journal-title":"Arch Intern Med"},{"issue":"9","key":"2024081912514602600_B27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archpedi.161.9.896","article-title":"Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005.","volume":"161","author":"Bravata","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"7","key":"2024081912514602600_B28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1086\/512372","article-title":"A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor.","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024081912514602600_B29","volume-title":"Prepositioning Antibiotics for Anthrax","author":"Stroud","year":"2012"},{"issue":"7","key":"2024081912514602600_B30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3201\/eid0807.020062","article-title":"Anthrax of the gastrointestinal tract.","volume":"8","author":"Sirisanthana","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"2024081912514602600_B31","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1001\/archinte.163.20.2527","article-title":"Gastrointestinal anthrax: review of the literature.","volume":"163","author":"Beatty","year":"2003","journal-title":"Arch Intern Med"},{"issue":"2\u20133","key":"2024081912514602600_B32","first-page":"205","article-title":"An outbreak of human gastrointestinal anthrax.","volume":"20","author":"Ndyabahinduka","year":"1984","journal-title":"Ann Ist Super Sanita"},{"issue":"6","key":"2024081912514602600_B33","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1073\/pnas.90.6.2291","article-title":"Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979.","volume":"90","author":"Abramova","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024081912514602600_B34","unstructured":"Centers for Disease Control and Prevention. Anthrax (Bacillus anthracis) 2010 case definition. Available at: wwwn.cdc.gov\/nndss\/script\/casedef.aspx?CondYrID=609&DatePub=1\/1\/2010%2012:00:00%20AM. Accessed August 21, 2013"},{"issue":"1","key":"2024081912514602600_B35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey.","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg (Lond)"},{"issue":"11","key":"2024081912514602600_B36","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1128\/aem.60.11.4167-4171.1994","article-title":"Formaldehyde solution effectively inactivates spores of Bacillus anthracis on the Scottish island of Gruinard.","volume":"60","author":"Manchee","year":"1994","journal-title":"Appl Environ Microbiol"},{"key":"2024081912514602600_B37","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"2024081912514602600_B38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax.","volume":"167","author":"Friedlander","year":"1993","journal-title":"J Infect Dis"},{"key":"2024081912514602600_B39","unstructured":"US Food and Drug Administration. How to prepare doxycycline for children and adults who cannot swallow pills. Available at: www.fda.gov\/downloads\/Drugs\/EmergencyPreparedness\/BioterrorismandDrugPreparedness\/UCM131001.pdf. Accessed August 21, 2013"},{"issue":"5","key":"2024081912514602600_B40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00006454-199805000-00019","article-title":"Doxycycline and staining of permanent teeth.","volume":"17","author":"Lochary","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2024081912514602600_B41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0009922806290026","article-title":"Absence of tooth staining with doxycycline treatment in young children.","volume":"46","author":"Volovitz","year":"2007","journal-title":"Clin Pediatr (Phila)"},{"issue":"5","key":"2024081912514602600_B42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/pds.1547","article-title":"Adverse events associated with prolonged antibiotic use.","volume":"17","author":"Meropol","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024081912514602600_B43","unstructured":"Presidential Commission for the Study of Bioethical Issues. Safeguarding children. Pediatric medical countermeasure research. March 2013. Available at: http:\/\/bioethics.gov\/node\/833. Accessed August 21, 2013"},{"issue":"2","key":"2024081912514602600_B44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/15459620903389558","article-title":"Anthrax letters: personal exposure, building contamination, and effectiveness of immediate mitigation measures.","volume":"7","author":"Kournikakis","year":"2010","journal-title":"J Occup Environ Hyg"},{"issue":"4","key":"2024081912514602600_B45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhin.2007.05.002","article-title":"Nosocomial spread of Bacillus anthracis.","volume":"66","author":"Yakupogullari","year":"2007","journal-title":"J Hosp Infect"},{"issue":"1","key":"2024081912514602600_B46","first-page":"96","article-title":"Human anthrax in Iran. Report of 300 cases and review of literature.","volume":"25","author":"Amidi","year":"1974","journal-title":"Tropenmed Parasitol"},{"issue":"9","key":"2024081912514602600_B47","first-page":"176","article-title":"A major epidemic of anthrax in Zimbabwe. The experience at the Beatrice Road Infectious Diseases Hospital, Harare.","volume":"31","author":"Davies","year":"1985","journal-title":"Cent Afr J Med"},{"issue":"3","key":"2024081912514602600_B48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1086\/596063","article-title":"A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.","volume":"199","author":"Vietri","year":"2009","journal-title":"J Infect Dis"},{"issue":"2","key":"2024081912514602600_B49","doi-asserted-by":"crossref","DOI":"10.3201\/eid2002.130687","article-title":"Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults","volume":"20","author":"Hendricks","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"2024081912514602600_B50","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s10096-012-1628-4","article-title":"Molecular epidemiology of the Bacillus anthracis isolates collected throughout Turkey from 1983 to 2011.","volume":"31","author":"Durmaz","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6935","key":"2024081912514602600_B51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature01586","article-title":"The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria.","volume":"423","author":"Read","year":"2003","journal-title":"Nature"},{"issue":"8","key":"2024081912514602600_B52","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1128\/JCM.42.8.3626-3634.2004","article-title":"MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.","volume":"42","author":"Turnbull","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"6","key":"2024081912514602600_B53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0924-8579(01)00464-2","article-title":"In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones.","volume":"18","author":"Brook","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2024081912514602600_B54","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2011-1496","article-title":"The use of systemic and topical fluoroquinolones.","volume":"128","author":"Bradley","year":"2011","journal-title":"Pediatrics"},{"issue":"4","key":"2024081912514602600_B55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/106002809703100418","article-title":"Treatment of Rocky Mountain spotted fever in children.","volume":"31","author":"Cale","year":"1997","journal-title":"Ann Pharmacother"},{"key":"2024081912514602600_B56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.med.51.1.271","article-title":"Streptococcal toxic shock syndrome associated with necrotizing fasciitis.","volume":"51","author":"Stevens","year":"2000","journal-title":"Annu Rev Med"},{"issue":"4","key":"2024081912514602600_B57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM199601253340407","article-title":"Streptococcal infections of skin and soft tissues.","volume":"334","author":"Bisno","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"2024081912514602600_B58","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00006454-199912000-00014","article-title":"Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.","volume":"18","author":"Zimbelman","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"2024081912514602600_B59","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1001\/jama.1921.02630510010004","article-title":"The local and general serum treatment of cutaneous anthrax.","volume":"77","author":"Regan","year":"1921","journal-title":"JAMA"},{"key":"2024081912514602600_B60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0140-6736(00)92864-2","article-title":"The treatment of human anthrax.","volume":"210","author":"Pijper","year":"1926","journal-title":"Lancet"},{"issue":"1","key":"2024081912514602600_B61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00000658-200207000-00004","article-title":"Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.","volume":"236","author":"Binkley","year":"2002","journal-title":"Ann Surg"},{"issue":"3","key":"2024081912514602600_B62","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1302\/0301-620X.93B3.25976","article-title":"Subcutaneous anthrax in three intravenous drug users: a new clinical diagnosis.","volume":"93","author":"Knox","year":"2011","journal-title":"J Bone Joint Surg Br"},{"issue":"4","key":"2024081912514602600_B63","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2214\/ajr.181.4.1811071","article-title":"Inhalational anthrax: radiologic and pathologic findings in two cases.","volume":"181","author":"Wood","year":"2003","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"2024081912514602600_B64","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2024081912514602600_B65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2024081912514602600_B66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/45.1.5","article-title":"Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis.","volume":"45","author":"Norrby","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2024081912514602600_B67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006454-199102000-00009","article-title":"Imipenem\/cilastatin treatment of bacterial meningitis in children.","volume":"10","author":"Wong","year":"1991","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2024081912514602600_B68","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jac\/dkr482","article-title":"Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis.","volume":"67","author":"Stucki","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2024081912514602600_B69","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1473-3099(05)70113-4","article-title":"Management of anthrax meningitis.","volume":"5","author":"Sejvar","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"2024081912514602600_B70","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/INF.0b013e3181df4b9a","article-title":"Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents.","volume":"29","author":"Yogev","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2024081912514602600_B71","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1128\/AAC.46.3.936-937.2002","article-title":"Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections.","volume":"46","author":"Villani","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2024081912514602600_B72","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/003655401750174048","article-title":"Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review.","volume":"33","author":"Shaikh","year":"2001","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"2024081912514602600_B73","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/AAC.40.1.122","article-title":"Clindamycin therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.","volume":"40","author":"Par\u00eds","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2024081912514602600_B74","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1086\/379012","article-title":"Linezolid-associated toxic optic neuropathy: a report of 2 cases.","volume":"37","author":"Lee","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2024081912514602600_B75","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","article-title":"Peripheral neuropathy associated with prolonged use of linezolid.","volume":"4","author":"Bressler","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"2024081912514602600_B76"},{"issue":"8","key":"2024081912514602600_B77","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience.","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"4749","key":"2024081912514602600_B78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/bmj.1.4749.86","article-title":"Chloramphenicol in treatment of cutaneous anthrax.","volume":"1","author":"Clarke","year":"1952","journal-title":"BMJ"},{"issue":"15","key":"2024081912514602600_B79","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM198810133191502","article-title":"Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials.","volume":"319","author":"Lebel","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"2024081912514602600_B80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mib.2003.12.001","article-title":"The roles of anthrax toxin in pathogenesis.","volume":"7","author":"Moayeri","year":"2004","journal-title":"Curr Opin Microbiol"},{"issue":"12","key":"2024081912514602600_B81","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2165\/00128072-200204120-00006","article-title":"Antibiotics and breastfeeding: a critical review of the literature.","volume":"4","author":"Chung","year":"2002","journal-title":"Paediatr Drugs"},{"issue":"4","key":"2024081912514602600_B82","doi-asserted-by":"publisher","DOI":"10.3201\/eid1404.070969","article-title":"Conference report on public health and clinical guidelines for anthrax.","volume":"14","author":"Stern","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"2024081912514602600_B83","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130611","article-title":"Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.","volume":"20","author":"Meaney-Delman","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2024081912514602600_B84"},{"issue":"4","key":"2024081912514602600_B85","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000076364","article-title":"Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections.","volume":"85","author":"Belet","year":"2004","journal-title":"Biol Neonate"},{"issue":"2","key":"2024081912514602600_B86","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/INF.0b013e3181fe353d","article-title":"Ciprofloxacin use in neonates: a systematic review of the literature.","volume":"30","author":"Kaguelidou","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"2024081912514602600_B87","first-page":"1001","article-title":"Multiple dose pharmacokinetics of ciprofloxacin in preterm babies.","volume":"41","author":"Aggarwal","year":"2004","journal-title":"Indian Pediatr"},{"issue":"4","key":"2024081912514602600_B88","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00003495-200868040-00011","article-title":"Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection.","volume":"68","author":"Anderson","year":"2008","journal-title":"Drugs"},{"issue":"4","key":"2024081912514602600_B89","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jinf.2008.08.002","article-title":"Mycoplasma hominis meningitis in a neonate: case report and review.","volume":"57","author":"Hata","year":"2008","journal-title":"J Infect"},{"issue":"2","key":"2024081912514602600_B90","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0b013e31823980c3","article-title":"Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.","volume":"31","author":"Watt","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2024081912514602600_B91","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/INF.0b013e318170f8d2","article-title":"Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.","volume":"27","author":"Bradley","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"2024081912514602600_B92","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/INF.0b013e31822e8b0b","article-title":"Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.","volume":"30","author":"Smith","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2024081912514602600_B93","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.00351-09","article-title":"Meropenem pharmacokinetics in the newborn.","volume":"53","author":"van den Anker","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"4\u20135","key":"2024081912514602600_B94","first-page":"299","article-title":"Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem\/cilastatin.","volume":"27","author":"B\u00f6swald","year":"1999","journal-title":"Infection"},{"issue":"7","key":"2024081912514602600_B95","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1128\/AAC.01149-05","article-title":"Prospective determination of plasma imipenem concentrations in critically ill children.","volume":"50","author":"Giannoni","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2024081912514602600_B96","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1128\/AAC.34.6.1172","article-title":"Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life.","volume":"34","author":"Reed","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2024081912514602600_B97","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1128\/AAC.01506-06","article-title":"Pharmacokinetics of penicillin g in very-low-birth-weight neonates.","volume":"51","author":"Metsvaht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2024081912514602600_B98","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00318-07","article-title":"Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.","volume":"51","author":"Muller","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2024081912514602600_B99","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/j.ijid.2009.10.002","article-title":"Use of linezolid in pediatrics: a critical review.","volume":"14","author":"Dotis","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"3","key":"2024081912514602600_B100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijantimicag.2005.11.006","article-title":"Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates.","volume":"27","author":"Hoehn","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2024081912514602600_B101","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijantimicag.2010.03.030","article-title":"Linezolid treatment of nosocomial bacterial infection with multiresistant gram-positive pathogens in preterm infants: a systematic review.","volume":"36","author":"Kocher","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2024081912514602600_B102","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0009-9236(03)00226-1","article-title":"Impact of ontogeny on linezolid disposition in neonates and infants.","volume":"74","author":"Kearns","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2024081912514602600_B103","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1651-2227.2002.tb03300.x","article-title":"Intravenous rifampicin in neonates with persistent staphylococcal bacteraemia.","volume":"91","author":"Shama","year":"2002","journal-title":"Acta Paediatr"},{"issue":"11","key":"2024081912514602600_B104","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1128\/AAC.37.11.2401","article-title":"Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.","volume":"37","author":"Tan","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081912514602600_B105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2431-10-84","article-title":"Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.","volume":"10","author":"van der Lugt","year":"2010","journal-title":"BMC Pediatr"},{"issue":"4","key":"2024081912514602600_B106","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/000992280204100402","article-title":"Tetracyclines in pediatrics revisited.","volume":"41","author":"Shetty","year":"2002","journal-title":"Clin Pediatr (Phila)"},{"issue":"2","key":"2024081912514602600_B107","first-page":"75","article-title":"A multicenter therapeutic study of 1100 children with brucellosis.","volume":"8","author":"Lubani","year":"1989","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"2024081912514602600_B108","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/INF.0b013e31817bf9a9","article-title":"Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations.","volume":"27","author":"Alexander","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"2024081912514602600_B109","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1021\/js970068l","article-title":"Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants.","volume":"86","author":"Charles","year":"1997","journal-title":"J Pharm Sci"},{"issue":"2","key":"2024081912514602600_B110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/AAC.39.2.431","article-title":"Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks.","volume":"39","author":"Huisman-de Boer","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2024081912514602600_B111","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.ftd.0000198648.39751.11","article-title":"Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates.","volume":"28","author":"Pullen","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"12","key":"2024081912514602600_B112","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.inf.0000245105.99934.5f","article-title":"Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development.","volume":"25","author":"Ahmed","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2024081912514602600_B113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003495-200262010-00002","article-title":"A critical review of the fluoroquinolones: focus on respiratory infections.","volume":"62","author":"Zhanel","year":"2002","journal-title":"Drugs"},{"issue":"3","key":"2024081912514602600_B114","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1542\/peds.47.3.567","article-title":"Tetracyclines and permanent teeth: the relation between dose and tooth color.","volume":"47","author":"Grossman","year":"1971","journal-title":"Pediatrics"},{"issue":"6","key":"2024081912514602600_B115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1085","article-title":"An overview of adverse events reported by participants in CDC\u2019s anthrax vaccine and antimicrobial availability program.","volume":"14","author":"Martin","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/5\/e1411\/1691723\/peds_2014-0563.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/5\/e1411\/1691723\/peds_2014-0563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T12:52:33Z","timestamp":1724071953000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/133\/5\/e1411\/32670\/Pediatric-Anthrax-Clinical-Management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":115,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,1]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-0563","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}